Alnylam Pharmaceuticals's latest marketcap:

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutics based on RNA interference (RNAi) technology.

Key Products

• ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis
• GIVLAARI for acute hepatic porphyria
• OXLUMO for primary hyperoxaluria type 1
• Leqvio for hypercholesterolemia

Pipeline Highlights

• Vutrisiran (Phase III) – Transthyretin amyloidosis (ATTR) with cardiomyopathy
• Nucresiran (Phase I) – ATTR amyloidosis
• Fitusiran (Phase III) – Hemophilia
• Cemdisiran (Phase III) – Myasthenia Gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy
• ALN-6400 (Phase I) – Bleeding disorders
• Zilebesiran (Phase II) – Hypertension
• Rapirosiran (Phase II) – Metabolic dysfunction-associated steatohepatitis
• ALN-4324 (Phase I) – Type 2 diabetes mellitus
• ALN-PNP (Phase I) – Non-alcoholic fatty liver disease
• ALN-APOC3 (Phase I) – Dyslipidemia
• Mivelsiran (Phase II) – Cerebral amyloid angiopathy; (Phase I) – Alzheimer’s disease
• ALN-HTT02 (Phase I) – Huntington’s disease
• ALN-SOD (Phase II) – SOD1 Amyotrophic lateral sclerosis
• Elebsiran (Phase II) – Hepatitis B and D virus infections
• ALN-BCAT (Phase I) – Hepatocellular carcinoma
• ALN-ANG3 – In development

Strategic Collaborations

Alnylam has partnerships with leading pharmaceutical companies, including:

• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Novartis AG
• PeptiDream, Inc.
• Dicerna Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.

Company Background

Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts.